Patheon Prepares for IPO With Updated Pricing Details
Patheon expects to price more than 30 million shares in the range of $19 to $22 per share for a initial public offering valued up to about $771 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 205
Audentes Gears Up for IPO With Updated Pricing
Audentes Therapeutics expects to price its 5 million shares in the range of $14 to $16, for an initial public offering valued up to $92 million.
How Badly Analysts Ditched Juno Therapeutics After Clinical Hold
Juno Therapeutics saw its shares sink on Friday after the U.S. Food and Drug Administration levied a clinical hold on its leukemia treatment.
Viagra Price Drops 50% as Drug Faces Competition
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
Juno Therapeutics Stumbles Over FDA Clinical Hold
Juno Therapeutics saw its shares sink early on Friday after the U.S. Food and Drug Administration (FDA) levied a clinical hold on its leukemia treatment.
Eleven Biotherapeutics Soars on Investigational Milestone
Shares of Eleven Biotherapeutics saw a handy gain early on Friday after the company announced that its Investigational New Drug application for EBI-031 has become effective.
PTC Therapeutics Wins on New DMD Agreement
PTC Therapeutics made waves on Thursday following a development in its nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment.
Why Flexion Therapeutics Is Adding 3 New Executives to Its Ranks
Flexion Therapeutics has announced that three new executives have joined the company in key marketing, medical affairs and market access roles.
Do Confidentiality Agreements Signal an Impending Medivation Acquisition?
France-based Sanofi has been pursuing Medivation, but the company has been reluctant in responding to these offers. However things could be changing.
Amedica Gears Up for Secondary Offering
Amedica expects to gain about $11 million in gross proceeds from an underwritten secondary offering. The entire offering is valued up to more than $12 million.
Insys Soars on Huge FDA Win
Insys Therapeutics announced that the FDA has approved its dronabinol oral solution, Syndros, for use in treating anorexia associated with weight loss in patients with AIDS.
4 Companies That Destroyed Shareholders Despite a Brexit Recovery
Despite Brexit absolutely rocking the market over a week ago, the broad markets made a solid comeback leading most people to believe that this was just one big head fake. Some companies made runs in…
How Major Pharma Is Faring After the Brexit
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy…
Why Array Is Making a Run
Array BioPharma Inc. (NASDAQ: ARRY) is watching its shares make a handy gain on Friday after making a key U.S. Food and Drug Administration (FDA) submission. The company announced the submission of a New…
Ampio Crashes After Late-Stage Trial Failure
Ampio Pharmaceuticals, Inc. (NYSEMKT: AMPE) is watching its shares get cut in half on Thursday after news of a failed late-stage trial. The company announced the results of its Ampion PIVOT clinical trial as well…